Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
University of California Irvine
Search grants from University of California Irvine
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Massachusetts Institute of Technology
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
The Role of SOX10 in Stemness of KIT+ Cells and Repairing Irradiated Salivary Glands
Regulation of FGF23 by DMP1 in Health and in Chronic Kidney Disease (CKD)
Synthesis of Bulk Chemicals & Drugs for Preclinical Use
Neural Control of Eye Movement
Methanol and Formic Acid Decomposition Channels on Clean and Modified Platinum Electrodes: Data for Theory of Dissociative Electron Transfer
Recently added grants:
Molecular Insights into the Uropathogenesis of MDR Acinetobacter baumannii
Simple and rapid POC detection for fungemia
Characterization of neutralizing antitoxins and epitopes in Clostridium difficile patients
Virus-host interactions governing alpha-herpesvirus genome delivery and neuroinvasion
Quantifying renal injury among the most commonly used clinical antibiotic combinations
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CA075019-006
Application #
6828778
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2003
Total Cost
Indirect Cost
Institution
Name
University of California Irvine
Department
Type
DUNS #
City
State
Country
Zip Code
Related projects
NIH 2003
N01 CA
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
/ University of California Irvine
NIH 2002
N01 CA
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
/ University of California Irvine
Publications
Beeram, M; Tan, Q-T N; Tekmal, R R et al.
(2007)
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
Ann Oncol 18:1323-8
Comments
Be the first to comment on this grant